Boston Scientific Corporation
Clinical trials sponsored by Boston Scientific Corporation, explained in plain language.
A global medical device company specializing in minimally invasive interventions.
Not investment advice. Company information is shown for context only. Clinical trials frequently fail.
Advertising disclosure. Links marked "(ad)" go to partners we have a commercial relationship with, either a broker where you can trade or a stock-research service, and we may earn a commission if you open an account or subscribe. This never affects what is shown here.
Upcoming readouts
Trials from this sponsor expected to report results within the next 12 months.
- Gel shield could spare prostate cancer patients from radiation damage Results expected Sep 2026 (estimated)
- Double whammy for AFib: single procedure aims to fix rhythm and prevent strokes Results expected Oct 2026 (estimated)
- New device targets recurrent brain tumors in early trial Results expected Oct 2026 (estimated)
- New hope for weight regain after gastric bypass: TORe procedure tested Results expected Nov 2026 (estimated)
- New registry aims to perfect heart ablation workflow Results expected Feb 2027 (estimated)
-
Experimental device aims to tackle medical condition
Disease control Not yet recruitingThis trial investigates a device that has not been approved by the U.S. FDA. It enrolls participants with a specific medical condition to see if the device is safe and works as intended. The study will compare outcomes in those who receive the device versus those who do not.
Sponsor: Boston Scientific Corporation • Aim: Disease control
Last updated Sep 20, 2026 00:00 UTC
-
Can a new mapping and ablation system fix recurring atrial fibrillation?
Disease control Not yet recruitingResearchers are testing the FARAFLEX Mapping and Pulsed Field Ablation System in people with atrial fibrillation who need a repeat ablation procedure. The trial compares the FARAFLEX system, which uses electrographic flow mapping and pulsed electric fields, against a control trea…
Sponsor: Boston Scientific Corporation • Aim: Disease control
Last updated Sep 17, 2026 00:00 UTC
-
New stent combo aims to prevent stroke in chinese patients
Disease control Not yet recruitingThis study tests a stent (Carotid WALLSTENT) used with a special brain protection system (ENROUTE NPS) in 60 Chinese patients with narrowed carotid arteries. The goal is to see if the combination can be safely delivered to prevent strokes. Patients must have significant artery na…
Sponsor: Boston Scientific Corporation • Aim: Disease control
Last updated Sep 03, 2026 00:00 UTC
-
Brain pacemaker targets seizures in Drug-Resistant epilepsy
Disease control Not yet recruitingThis pilot study tests a deep brain stimulation device that sends electrical pulses to two brain areas (STN and CM) to reduce seizures in adults with drug-resistant motor epilepsy. Ten participants will have the device implanted and will be monitored for changes in seizure freque…
Sponsor: Boston Scientific Corporation • Aim: Disease control
Last updated Sep 03, 2026 00:00 UTC
-
Smarter radiation planning aims to boost liver tumor attack while sparing healthy tissue
Disease control Not yet recruitingThis study tests a new planning method called multicompartment dosimetry (MCD) for TheraSphere, a treatment that delivers tiny radioactive beads to liver tumors. The goal is to give a higher radiation dose to the tumor while protecting healthy liver. Researchers will enroll 140 p…
Sponsor: Boston Scientific Corporation • Aim: Disease control
Last updated Aug 30, 2026 00:00 UTC
-
Stomach-shrinking procedure may help control blood sugar and delay insulin in type 2 diabetes
Disease control Not yet recruitingThis trial tests whether a weight-loss procedure called endoscopic sleeve gastroplasty (ESG) can improve blood sugar control and reduce the need for insulin in adults with obesity and type 2 diabetes. Participants have poorly controlled diabetes despite taking standard medication…
Sponsor: Boston Scientific Corporation • Aim: Disease control
Last updated Aug 23, 2026 00:00 UTC
-
5,000-Patient registry to test new artery device in Real-World use
Disease control Not yet recruitingThis study will follow 5,000 adults with carotid artery disease who receive a treatment called TCAR using the ENROUTE system. The goal is to see how safe and effective the device is in real-world settings, especially for groups not well-studied before. Researchers will track majo…
Sponsor: Boston Scientific Corporation • Aim: Disease control
Last updated Jul 18, 2026 00:00 UTC